Bryn Mawr Capital Management LLC Decreases Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Bryn Mawr Capital Management LLC cut its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 10.0% in the 4th quarter, Holdings Channel.com reports. The firm owned 10,065 shares of the medical research company’s stock after selling 1,117 shares during the quarter. Bryn Mawr Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $5,236,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. AMF Tjanstepension AB purchased a new position in shares of Thermo Fisher Scientific during the third quarter worth about $42,409,000. Howard Capital Management Group LLC boosted its holdings in Thermo Fisher Scientific by 0.5% during the 3rd quarter. Howard Capital Management Group LLC now owns 54,575 shares of the medical research company’s stock valued at $33,759,000 after acquiring an additional 286 shares during the period. Arkadios Wealth Advisors increased its stake in shares of Thermo Fisher Scientific by 2.1% in the third quarter. Arkadios Wealth Advisors now owns 1,273 shares of the medical research company’s stock worth $787,000 after buying an additional 26 shares during the period. Autumn Glory Partners LLC raised its stake in shares of Thermo Fisher Scientific by 107.1% during the third quarter. Autumn Glory Partners LLC now owns 1,367 shares of the medical research company’s stock valued at $846,000 after acquiring an additional 707 shares during the last quarter. Finally, Orrstown Financial Services Inc. lifted its holdings in Thermo Fisher Scientific by 251.0% in the 3rd quarter. Orrstown Financial Services Inc. now owns 1,811 shares of the medical research company’s stock worth $1,120,000 after buying an additional 1,295 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $175,677.00. Following the transaction, the executive vice president now owns 16,363 shares of the company’s stock, valued at approximately $9,582,009.17. This represents a 1.80 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Stephen Williamson sold 9,825 shares of the company’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the sale, the chief financial officer now directly owns 27,296 shares of the company’s stock, valued at $15,984,264.64. The trade was a 26.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 20,125 shares of company stock worth $11,231,699 in the last ninety days. Insiders own 0.34% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Wells Fargo & Company boosted their price objective on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the company an “overweight” rating in a research report on Friday, January 31st. StockNews.com raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Tuesday, January 14th. Bank of America cut their price objective on Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. Sanford C. Bernstein upgraded Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 target price for the company in a research note on Friday, January 10th. Finally, UBS Group upped their price target on Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a “buy” rating in a research note on Friday, January 31st. Four equities research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $656.86.

Thermo Fisher Scientific Stock Up 0.8 %

TMO stock opened at $539.86 on Wednesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. Thermo Fisher Scientific Inc. has a 1-year low of $493.30 and a 1-year high of $627.88. The stock has a market capitalization of $206.50 billion, a P/E ratio of 32.66, a P/E/G ratio of 2.99 and a beta of 0.77. The business has a fifty day moving average price of $548.80 and a 200-day moving average price of $566.46.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific declared that its Board of Directors has approved a share buyback program on Friday, November 15th that authorizes the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to repurchase up to 2% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s board believes its shares are undervalued.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a yield of 0.32%. Thermo Fisher Scientific’s payout ratio is currently 10.41%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.